Dr. Yondola is Vice President, Research and Development at Calder Biosciences Inc. in Brooklyn, NY. Dr. Yondola has extensive training in virology and vaccine development and his work is currently focused on designing and developing conformationally stabilized recombinant subunit vaccines immunogens for respiratory syncytial virus and influenza virus. Calder utilizes a conformational stabilization technology based on targeted dityrosine crosslinks that are engineered into proteins/complexes in order to develop otherwise intractable vaccines. He obtained his Ph.D. from Stony Brook University where his work focused on the biochemical and biophysical characterization of the adenovirus E4-ORF3 protein and his postdoctoral training was at the Mt. Sinai Medical Center focusing on influenza virus biology and universal influenza virus vaccine development. Dr. Yondola, has been at Calder Biosciences since 2013, where he headed the universal influenza and respiratory syncytial virus vaccine programs, and now directs the company’s research & development.